🇺🇸 FDA
Pipeline program

Alkotinib Capsules

ZGALK002

Phase 2 small_molecule terminated

Quick answer

Alkotinib Capsules for ALK-positive Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Suzhou Zelgen Biopharmaceuticals Co.,Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Indication
ALK-positive Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials